Nov 5, 4:16 PM ET
Dentsply Sirona reported third-quarter 2026 net sales of $836 million, down 7.6% from $904 million a year earlier, and adjusted EPS of $0.29, down 29.4% from $0.42. GAAP results improved from a year earlier, when large impairment charges produced a $427 million net loss attributable to the company, but the company's cash flow weakened and it updated its 2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30.
- Net sales were $836 million, down 7.6% as reported and down 7.0% in constant currency.
- GAAP diluted loss was $0.01 per share, compared with a $2.14 loss per share a year earlier; adjusted EPS was $0.29 versus $0.42.
- The 2026 outlook calls for approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding a $0.17 one-time benefit from tariff refunds.
- Operating cash flow was $32 million versus $79 million, and free cash flow was $0 million versus $40 million; the company repurchased shares for approximately $13 million.
Read the filing on SEC.gov ↗
Oct 9, 4:16 PM ET
DENTSPLY SIRONA obtained lender consent and amended its revolving credit facility and three note purchase agreements, effective around September 30, 2026. The changes raise the maximum permitted leverage ratios for the quarters ending September 30 and December 31, 2026, and add tighter limits on new liens, subsidiary debt and restricted payments. The company says the revised terms are intended to keep it in compliance with its debt covenants in all material respects.
- Maximum permitted Total Leverage Ratio and Senior Leverage Ratio increased for fiscal quarters ending September 30, 2026 and December 31, 2026.
- Until the compliance certificate for fiscal 2026 is delivered, new liens and new subsidiary debt are generally prohibited, and restricted payments are limited with certain carveouts.
- Credit facility adds a new pricing level for the applicable margin and facility fee; note interest increases if leverage meets specified thresholds.
Read the filing on SEC.gov ↗
Jun 11, 8:32 AM ET
Dentsply Sirona appointed John Fortson as Executive Vice President and Chief Financial Officer, effective July 20, 2026, under an offer letter dated May 30, 2026. Fortson most recently served as President and CFO of Kymera International, and previously was CEO of Ingevity Corporation. The CFO change is a senior finance leadership transition, and the filing discloses his pay and sign-on terms.
- Base salary of $780,000 with a target annual bonus of 85% of base salary, prorated for 2026
- Beginning in 2027, annual equity award with a target grant date fair value of $2,500,000
- Sign-on cash payment of $500,000 and sign-on equity award with a target grant date fair value of $700,000
Read the filing on SEC.gov ↗
May 5, 4:18 PM ET
Dentsply Sirona reported first-quarter 2026 net sales of $880 million, up 0.1% from $879 million a year earlier, but posted a GAAP net loss attributable to the company of $10 million, or $0.05 per diluted share, compared with net income of $20 million, or $0.10 per share, in the first quarter of 2025. Restructuring and other costs of $67 million and a $32 million tax benefit shaped the result, and adjusted EPS fell 39.0% to $0.27. The company kept its 2026 outlook for net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.
- Net sales of $880 million, up 0.1% from $879 million; constant currency sales fell 6.7%
- GAAP net loss attributable to Dentsply Sirona of $10 million, or $0.05 per diluted share, versus net income of $20 million, or $0.10, a year earlier
- Adjusted EPS of $0.27 versus $0.44 a year earlier, down 39.0%; adjusted EBITDA of $129 million versus $168 million
- 2026 outlook maintained: net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.